RemeGen (REGMF) News Today $5.06 0.00 (0.00%) As of 09/8/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock REGMF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period RemeGen Co., Ltd. Engages in Wealth Management Product PurchaseAugust 29, 2025 | tipranks.comRemeGen Co., Ltd. Updates Articles of Association Following Share PlacementAugust 22, 2025 | tipranks.comRemeGen’s RC148 Receives Breakthrough Therapy Designation for Lung Cancer TreatmentAugust 19, 2025 | tipranks.comRemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countriesAugust 18, 2025 | prnewswire.comRemeGen Partners with Santen China for RC28-E CommercializationAugust 18, 2025 | tipranks.comRemeGen Co., Ltd. Invests in Wealth Management Product for Strategic Cash ManagementAugust 12, 2025 | tipranks.comRemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDAAugust 8, 2025 | prnewswire.comRemeGen Co., Ltd. Announces 2025 H Shareholders Meeting to Discuss Key Governance ChangesJuly 14, 2025 | tipranks.comRemeGen Co., Ltd. Announces Successful AGM and Shareholder Meeting ResultsJune 26, 2025 | tipranks.comPureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private PlacementJune 26, 2025 | businesswire.comRemeGen Partners with Vor Biopharma for Global Expansion of TelitaciceptJune 25, 2025 | tipranks.comRemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia GravisJune 17, 2025 | prnewswire.comRemeGen’s Telitacicept Gains Approval for Myasthenia Gravis Treatment in ChinaMay 27, 2025 | tipranks.comRemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in ChinaMay 27, 2025 | prnewswire.comRemeGen Co., Ltd. Enhances Governance with New Remuneration CommitteeMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Announces Strategic Governance Changes at 2025 Shareholder MeetingMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Announces 2024 AGM with Key ResolutionsMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Enhances Corporate Governance with New Nomination CommitteeMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Strengthens Governance with New Audit CommitteeMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Announces Board Composition and RolesMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Updates Nomination Committee to Enhance GovernanceMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Proposes Amendments to Enhance Corporate GovernanceMay 26, 2025 | tipranks.comRemeGen Co., Ltd. Announces New H Shares Placement to Raise HK$806 MillionMay 21, 2025 | tipranks.comRemeGen Co., Ltd. Schedules Board Meeting to Review Q1 2025 ResultsApril 14, 2025 | tipranks.comRemegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia GravisApril 8, 2025 | prnewswire.comRemeGen Co., Ltd. Announces Board Composition and Leadership RolesApril 2, 2025 | tipranks.comRemeGen Co., Ltd. Announces New Executive Director AppointmentApril 2, 2025 | tipranks.comRemeGen’s Telitacicept Study Gains Spotlight at 2025 AAN MeetingMarch 17, 2025 | tipranks.comRemeGen Co., Ltd. Schedules Board Meeting to Review Annual Results and Dividend ConsiderationMarch 17, 2025 | tipranks.comRemeGen Co., Ltd. Reports 2024 Financial Results with Increased Revenue but Continued LossesFebruary 27, 2025 | tipranks.comRemeGen Co., Ltd. Announces Board Composition and RolesFebruary 6, 2025 | tipranks.comRemeGen Projects Significant Revenue Growth Amid Loss Reduction in 2024January 16, 2025 | tipranks.comRemeGen Co., Ltd. Reveals Board Composition and RolesJanuary 10, 2025 | tipranks.comRemeGen Co., Ltd. Announces New Board Appointment at 2025 EGMJanuary 10, 2025 | tipranks.comRemeGen Co. Ltd. to Strengthen Leadership with New DirectorDecember 23, 2024 | tipranks.comRemeGen Co., Ltd. Announces H Shares Register ClosureDecember 19, 2024 | tipranks.com Get RemeGen News Delivered to You Automatically Sign up to receive the latest news and ratings for REGMF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REGMF Media Mentions By Week REGMF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGMF News Sentiment▼0.000.70▲Average Medical News Sentiment REGMF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGMF Articles This Week▼01▲REGMF Articles Average Week Get the Latest News and Ratings for REGMF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for RemeGen and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SXTPW News AGNPF News AKBLF News DRTSW News ASPHF News ASCLF News AVCTF News AWKNF News BRRGF News BCTXW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:REGMF) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhy This Critical Minerals Explorer Caught Rio Tinto’s EyeAs U.S. defense spending crosses $1 trillion, drones, hypersonics, and next-gen aerospace are taking center st...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RemeGen Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share RemeGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGMF Stock Alerts